查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1596234

視網膜病變治療藥物市場：按類型、劑型、分銷管道分類 - 全球預測 2025-2030

Retinal Disorder Treatment Market by Type (Diabetic Retinopathy, Macular Degeneration), Dosage Form (Capsules & Tablets, Eye Drops, Eye Solutions), Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年視網膜病變治療市值為86.2億美元，預計2024年將達到93.8億美元，複合年成長率為8.94%，到2030年將達到157億美元。

視網膜病變藥物市場包括旨在控制影響視網膜的疾病的各種治療策略，例如老齡化黃斑部病變、糖尿病視網膜病變和視網膜剝離。由於人口老化以及糖尿病和高血壓盛行率上升，需要這些治療。治療方法包括抗 VEGF 注射、雷射治療和手術介入等藥物治療。應用範圍廣泛，針對醫院、眼科診所、研究所等醫療環境。該市場預計將成長，特別是隨著基因治療和幹細胞研究技術的進步並提供有前景的解決方案和成果。關鍵的成長要素包括老年人口的成長、技術的進步以及醫療保健提供者對早期療育的認知的提高。潛在的機會在於遠端醫療服務以及預測分析和個人化醫療的人工智慧整合。公司可以透過投資研發、利用巨量資料分析和建立策略夥伴關係來利用這些優勢。然而，治療成本上升、監管障礙以及低度開發地區的准入有限等限制因素。此外，新興市場缺乏熟練的眼科醫生和醫療基礎設施不足等挑戰也可能阻礙成長。市場競爭仍然激烈，需要持續創新，重點是改進具有成本效益的治療解決方案和配方。需要創新的領域包括開發非侵入性治療方法和增強輸送系統以提高患者的依從性。該市場的特點是快速的技術適應導致治療模式的重大轉變。為了取得成功，公司必須保持敏捷，優先考慮跨部門協作，並維持強大的新產品開發管道。總體而言，使策略性舉措與新興趨勢保持一致對於維持市場相關性並實現視網膜病變治療領域的業務成長至關重要。

主要市場統計
基準年[2023] 86.2億美元
預測年份 [2024] 93.8億美元
預測年份 [2030] 157億美元
複合年成長率（%） 8.94%

市場動態：快速發展的視網膜病變治療市場的關鍵市場洞察

供需的動態交互作用正在改變視網膜病變藥物市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 監管機構增加對眼科疾病研究的資助
    • 全球視網膜疾病盛行率不斷上升
    • 黃斑部病變導致老年人口增加
  • 市場限制因素
    • 研發成本高
  • 市場機會
    • 治療方面的創新與進步
    • 擴大策略聯盟並將新產品商業化
  • 市場挑戰
    • 可能出現眼部併發症

波特五力：駕馭視網膜疾病藥物市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解視網膜病變治療藥物市場的外部影響

外部宏觀環境因素在塑造視網膜疾病治療藥物市場的表現動態中發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解視網膜疾病治療藥物市場的競爭狀況

對視網膜病變治療藥物市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣視網膜病變治療市場供應商的績效評估

FPNV 定位矩陣是評估視網膜病變治療市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，描繪視網膜病變治療市場的成功之路

對於旨在加強在全球市場的影響力的公司來說，視網膜病變治療藥物市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 眼科疾病研究的監管經費增加
      • 全球視網膜疾病的盛行率正在增加
      • 老年人口增加和黃斑部病變
    • 抑制因素
      • 研發活動成本高
    • 機會
      • 技術創新和治療方法進步
      • 擴大策略合作並將新產品商業化
    • 任務
      • 可能出現眼部併發症
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章視網膜病變治療藥物市場：依類型

  • 糖尿病視網膜病變
  • 黃斑部病變
    • 乾性黃斑部病變
    • 濕性黃斑部病變

第7章依劑型分類的視網膜病變治療藥物市場

  • 膠囊和片劑
  • 眼藥水
  • 眼液
  • 凝膠
  • 軟膏

第8章視網膜病變治療藥物市場：依分銷管道

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第9章北美和南美視網膜疾病治療藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太視網膜病變治療藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章：歐洲、中東和非洲視網膜病變治療藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • AbbVie Inc.
  • Abeona Therapeutics Inc.
  • Apellis Pharmaceuticals, Inc.
  • Bausch & Lomb Incorporated
  • Bayer AG
  • F. Hoffmann-La Roche Ltd.
  • Graybug Vision Inc.
  • Kubota Pharmaceutical Holdings Co., Ltd.
  • Novartis AG
  • ONL Therapeutics
  • Opthea
  • Oxford Biomedica PLC
  • Oxurion NV
  • Pfizer, Inc.
  • Regeneron Pharmaceuticals Inc.
  • Santen Pharmaceutical Co., Ltd.
  • Spark Therapeutics, Inc.
Product Code: MRR-CA17E905E6E9

The Retinal Disorder Treatment Market was valued at USD 8.62 billion in 2023, expected to reach USD 9.38 billion in 2024, and is projected to grow at a CAGR of 8.94%, to USD 15.70 billion by 2030.

The retinal disorder treatment market encompasses a range of therapeutic strategies aimed at managing conditions affecting the retina, such as age-related macular degeneration, diabetic retinopathy, and retinal detachment. The necessity for these treatments stems from the increasing prevalence of these disorders, largely driven by an aging population and rising incidence of diabetes and hypertension. Treatments include pharmacologic therapies, such as anti-VEGF injections, laser treatments, and surgical interventions. The application scope is broad, targeting healthcare settings like hospitals, ophthalmology clinics, and research institutes. The market is poised for growth due to advancing technologies, particularly in gene therapy and stem cell research, offering promising solutions and outcomes. Key growth influencers include the rising geriatric population, technological advancements, and increased awareness among healthcare providers regarding early intervention. Potential lucrative opportunities lie in telemedicine services and the integration of AI for predictive analytics and personalized medicine. Companies can capitalize on these by investing in research and development, leveraging big data analytics, and forming strategic partnerships. However, limitations include high treatment costs, regulatory hurdles, and limited access in underdeveloped regions. Additionally, challenges such as a shortage of skilled ophthalmologists and insufficient healthcare infrastructure in emerging markets could impede growth. The market remains highly competitive with a need for continuous innovation, demanding a focus on cost-effective therapeutic solutions and improved drug formulations. Areas ripe for innovation include developing non-invasive treatment methodologies and enhanced delivery systems to improve patient compliance. The market is nature-driven by rapid technological adaptation, leading to substantial shifts in treatment paradigms. Successful navigation requires companies to remain agile, prioritize cross-sector collaborations, and maintain robust pipelines for new product development. Overall, aligning strategic initiatives with emerging trends will be vital for sustaining market relevance and achieving business growth in the retinal disorder treatment domain.

KEY MARKET STATISTICS
Base Year [2023] USD 8.62 billion
Estimated Year [2024] USD 9.38 billion
Forecast Year [2030] USD 15.70 billion
CAGR (%) 8.94%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Retinal Disorder Treatment Market

The Retinal Disorder Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing funding by regulatory bodies for research on ocular disorders
    • Increasing prevalence of retinal disorders globally
    • Rising elderly population coupled with macular degeneration
  • Market Restraints
    • High cost involved in research and development activities
  • Market Opportunities
    • Technological innovations and advancements in treatments
    • Growing strategic collaborations and commercialization of novel products
  • Market Challenges
    • Probable complications in the eye

Porter's Five Forces: A Strategic Tool for Navigating the Retinal Disorder Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Retinal Disorder Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Retinal Disorder Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Retinal Disorder Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Retinal Disorder Treatment Market

A detailed market share analysis in the Retinal Disorder Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Retinal Disorder Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Retinal Disorder Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Retinal Disorder Treatment Market

A strategic analysis of the Retinal Disorder Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Retinal Disorder Treatment Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Abeona Therapeutics Inc., Apellis Pharmaceuticals, Inc., Bausch & Lomb Incorporated, Bayer AG, F. Hoffmann-La Roche Ltd., Graybug Vision Inc., Kubota Pharmaceutical Holdings Co., Ltd., Novartis AG, ONL Therapeutics, Opthea, Oxford Biomedica PLC, Oxurion NV, Pfizer, Inc., Regeneron Pharmaceuticals Inc., Santen Pharmaceutical Co., Ltd., and Spark Therapeutics, Inc..

Market Segmentation & Coverage

This research report categorizes the Retinal Disorder Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Diabetic Retinopathy and Macular Degeneration. The Macular Degeneration is further studied across Dry Macular Degeneration and Wet Macular Degeneration.
  • Based on Dosage Form, market is studied across Capsules & Tablets, Eye Drops, Eye Solutions, Gels, and Ointments.
  • Based on Distribution Channel, market is studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing funding by regulatory bodies for research on ocular disorders
      • 5.1.1.2. Increasing prevalence of retinal disorders globally
      • 5.1.1.3. Rising elderly population coupled with macular degeneration
    • 5.1.2. Restraints
      • 5.1.2.1. High cost involved in research and development activities
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological innovations and advancements in treatments
      • 5.1.3.2. Growing strategic collaborations and commercialization of novel products
    • 5.1.4. Challenges
      • 5.1.4.1. Probable complications in the eye
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Retinal Disorder Treatment Market, by Type

  • 6.1. Introduction
  • 6.2. Diabetic Retinopathy
  • 6.3. Macular Degeneration
    • 6.3.1. Dry Macular Degeneration
    • 6.3.2. Wet Macular Degeneration

7. Retinal Disorder Treatment Market, by Dosage Form

  • 7.1. Introduction
  • 7.2. Capsules & Tablets
  • 7.3. Eye Drops
  • 7.4. Eye Solutions
  • 7.5. Gels
  • 7.6. Ointments

8. Retinal Disorder Treatment Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Hospital Pharmacy
  • 8.3. Online Pharmacy
  • 8.4. Retail Pharmacy

9. Americas Retinal Disorder Treatment Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Retinal Disorder Treatment Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Retinal Disorder Treatment Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Abeona Therapeutics Inc.
  • 3. Apellis Pharmaceuticals, Inc.
  • 4. Bausch & Lomb Incorporated
  • 5. Bayer AG
  • 6. F. Hoffmann-La Roche Ltd.
  • 7. Graybug Vision Inc.
  • 8. Kubota Pharmaceutical Holdings Co., Ltd.
  • 9. Novartis AG
  • 10. ONL Therapeutics
  • 11. Opthea
  • 12. Oxford Biomedica PLC
  • 13. Oxurion NV
  • 14. Pfizer, Inc.
  • 15. Regeneron Pharmaceuticals Inc.
  • 16. Santen Pharmaceutical Co., Ltd.
  • 17. Spark Therapeutics, Inc.

LIST OF FIGURES

  • FIGURE 1. RETINAL DISORDER TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. RETINAL DISORDER TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY DOSAGE FORM, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY DOSAGE FORM, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS RETINAL DISORDER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS RETINAL DISORDER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC RETINAL DISORDER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC RETINAL DISORDER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. RETINAL DISORDER TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. RETINAL DISORDER TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. RETINAL DISORDER TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. RETINAL DISORDER TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY DIABETIC RETINOPATHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY DRY MACULAR DEGENERATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY WET MACULAR DEGENERATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY CAPSULES & TABLETS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY EYE DROPS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY EYE SOLUTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY GELS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY OINTMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS RETINAL DISORDER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS RETINAL DISORDER TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS RETINAL DISORDER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA RETINAL DISORDER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA RETINAL DISORDER TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL RETINAL DISORDER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL RETINAL DISORDER TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA RETINAL DISORDER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA RETINAL DISORDER TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO RETINAL DISORDER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO RETINAL DISORDER TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC RETINAL DISORDER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC RETINAL DISORDER TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC RETINAL DISORDER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA RETINAL DISORDER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA RETINAL DISORDER TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA RETINAL DISORDER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA RETINAL DISORDER TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA RETINAL DISORDER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA RETINAL DISORDER TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA RETINAL DISORDER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA RETINAL DISORDER TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN RETINAL DISORDER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN RETINAL DISORDER TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA RETINAL DISORDER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA RETINAL DISORDER TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES RETINAL DISORDER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES RETINAL DISORDER TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE RETINAL DISORDER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE RETINAL DISORDER TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA RETINAL DISORDER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA RETINAL DISORDER TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN RETINAL DISORDER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN RETINAL DISORDER TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND RETINAL DISORDER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND RETINAL DISORDER TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM RETINAL DISORDER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM RETINAL DISORDER TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK RETINAL DISORDER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK RETINAL DISORDER TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT RETINAL DISORDER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT RETINAL DISORDER TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND RETINAL DISORDER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND RETINAL DISORDER TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE RETINAL DISORDER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE RETINAL DISORDER TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY RETINAL DISORDER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY RETINAL DISORDER TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL RETINAL DISORDER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL RETINAL DISORDER TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY RETINAL DISORDER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY RETINAL DISORDER TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS RETINAL DISORDER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS RETINAL DISORDER TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA RETINAL DISORDER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA RETINAL DISORDER TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY RETINAL DISORDER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY RETINAL DISORDER TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND RETINAL DISORDER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND RETINAL DISORDER TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR RETINAL DISORDER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR RETINAL DISORDER TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA RETINAL DISORDER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA RETINAL DISORDER TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA RETINAL DISORDER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA RETINAL DISORDER TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN RETINAL DISORDER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN RETINAL DISORDER TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN RETINAL DISORDER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN RETINAL DISORDER TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND RETINAL DISORDER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND RETINAL DISORDER TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY RETINAL DISORDER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY RETINAL DISORDER TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES RETINAL DISORDER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES RETINAL DISORDER TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM RETINAL DISORDER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM RETINAL DISORDER TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 191. RETINAL DISORDER TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 192. RETINAL DISORDER TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023